Syntimmune - Ownership and Business Overview

Life ScienceCompany

Syntimmune Ownership

Who owns Syntimmune?

Syntimmune is owned by Alexion Pharmaceuticals. It was acquired on September 26, 2018.

Syntimmune Business Overview

Where is Syntimmune headquartered?

Syntimmune is headquartered in Boston, Massachusetts.

What sector is Syntimmune in?

Syntimmune is a life science company.

When was Syntimmune founded?

Syntimmune was founded in 2013.

Life Science M&A Summary in 2018

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2018. The largest life science acquisition in 2018 was Shire - which was acquired by Takeda Pharmaceutical for $67.7B.

Join Mergr to view all 246 acquisitions of life science companies in 2018, including 44 acquisitions by private equity firms, and 202 by strategics.

Syntimmune

116 Huntington Ave, Suite 301,
Boston, Massachusetts 02116
United States,
(617) 206-4220
www.syntimmune.com

Syntimmune is a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases. Drawing on the pioneering research of its scientific founders, the company is advancing novel therapies based on its deep expertise in the biology of the neonatal Fc receptor (FcRn) and its complex role in the pathogenesis of IgG-mediated autoimmune diseases. Syntimmune’s lead candidate, SYNT001, is a monoclonal antibody that specifically blocks FcRn-IgG interactions and is being studied in multiple Phase 1b/2a trials for the treatment of IgG-mediated autoimmune diseases. Syntimmune is headquartered in Boston, Mass. and was founded in 2013.


 Subscribe to unlock this and 207,877
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 200K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.